Literature DB >> 23257515

Clinical features of cirrhosis in Japanese patients with type I autoimmune hepatitis.

Kazumichi Abe1, Fumiko Katsushima, Yukiko Kanno, Atsushi Takahashi, Junko Yokokawa, Hiromasa Ohira, Teruko Arinaga, Tatsuya Ide, Junko Nishimura, Megumi Inoue, Masataka Seike, Fumio Imazeki, Osamu Yokosuka, Michio Sata.   

Abstract

OBJECTIVE: Autoimmune hepatitis (AIH) is a chronic inflammatory disorder of unknown etiology that may proceed to cirrhosis, although some patients already have cirrhosis at the time of AIH diagnosis. The aim of this study was to clarify the clinical characteristics of AIH patients with cirrhosis in Japan.
METHODS: Questionnaires were sent to liver specialists at four research facilities. Data for 250 patients diagnosed with AIH using the scoring system of the International Autoimmune Hepatitis Group (IAIHG) between 1975 and 2010 were collected and analyzed.
RESULTS: The male-to-female ratio was 1:8.3 and the average patient age was 55.6 years. Liver cirrhosis was found in 51 AIH patients (20.4%). Of these, 43 patients (84.3%) had cirrhosis at presentation and eight patients (15.7%) developed cirrhosis during the follow-up period (average follow-up of 82.1 months). There were significant differences between the two groups with and without cirrhosis at presentation with regard to age and biochemical parameters at presentation. There were no significant differences in histology, with the exception of liver fibrosis. The overall 10-year probability of survival was 71.2% vs. 99.3% in the patients with and without cirrhosis (log-rank test, p<0.001). The relapse rate was significantly higher in the patients who developed cirrhosis during treatment than in those who did not develop cirrhosis during treatment (100% vs. 7.5%, p<0.001).
CONCLUSION: Since liver cirrhosis has already developed at presentation in many AIH patients with cirrhosis, it is important to diagnose the disease in the early stage and administer treatment rapidly with corticosteroids or immunosuppressants. In addition, a history of relapse is a risk factor for the development of cirrhosis in Japanese patients with AIH.

Entities:  

Mesh:

Year:  2012        PMID: 23257515     DOI: 10.2169/internalmedicine.51.8372

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.

Authors:  Zhaoyue Wang; Li Sheng; Yue Yang; Fan Yang; Xiao Xiao; Jing Hua; Canjie Guo; Yiran Wei; Ruqi Tang; Qi Miao; Jun Zhang; Yanmei Li; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; Christopher L Bowlus; M Eric Gershwin; Qixia Wang; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 2.  Auto immune hepatitis.

Authors:  Nicole Mf van Gerven; Ynto S de Boer; Chris Jj Mulder; Carin Mj van Nieuwkerk; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

Review 4.  Autoimmune Hepatitis in the Asia-Pacific Area.

Authors:  Qi-Xia Wang; Li Yan; Xiong Ma
Journal:  J Clin Transl Hepatol       Date:  2017-12-07

5.  Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by iTRAQ Proteomics.

Authors:  Zheng Minghui; Hu Kunhua; Bao Yunwen; Lu Hongmei; Li Jing; Wu Shaowen; Sun Longqiaozi; Duan Chaohui
Journal:  Proteomics Clin Appl       Date:  2018-08-09       Impact factor: 3.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.